Serum cystatin C level is a useful marker for the evaluation of renal function in patients with cirrhotic ascites and normal serum creatinine levels by Kim, Dong Jin et al.
The Korean Journal of Hepatology 2011;17:130-138
DOI: 10.3350/kjhep.2011.17.2.130 Original Article
Serum cystatin C level is a useful marker for the evaluation 
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Background/Aims: Several studies suggested that serum cystatin C (CysC) is more useful than serum creatinine (Cr) for the 
assessment of renal function in patients with liver cirrhosis. This study evaluated the clinical significance of CysC in patients with 
cirrhotic ascites and normal Cr level. Methods: We enrolled patients with cirrhotic ascites and a normal serum Cr level (<1.2 
mg/dL). GFR was measured by 
99mTc- DTPA renal scan. Serum Cr, CysC, and Cr clearance (CCr) were measured on the same 
day. Significant renal impairment and severe renal impairment were defined as GFR <60 mL/min and GFR <30 mL/min, 
respectively. Results: Eighty-nine patients with cirrhotic ascites were enrolled in the study (63 men and 26 women; age, 55±11 
years). Forty-seven (52.8%) and 42 (47.2%) patients were in Child-Pugh grade B and C, respectively. Serum Cr and CysC levels 
and GFR were 0.8±0.2 mg/dL, 1.1±0.3 mg/L, and 73.4±25.5 mL/min, respectively. Significant and severe renal impairment were 
noted in 28 (31.5%) and 2 (2.2%) patients, respectively. GFR was well correlated with serum Cr, CysC, and e-GFRMDRD, while it 
was not correlated with e-GFRC&G. In multivariate analysis, only CysC was significantly correlated with GFR (β, 45.620; 95% CI, 
23.042-68.198; P<0.001). Serum CysC level was the only independent predictor for significant renal impairment. Conclusions: 
Significant renal dysfunction was not rare in patients with cirrhotic ascites, even their serum Cr level is normal. Serum CysC is a 
useful marker for detecting significant renal dysfunction in these patients. (Korean J Hepatol 2011;17:130-138)
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INTRODUCTION
Renal dysfunction is common in patients with liver 
cirrhosis, which occurs about 19% of hospitalized patients 
with cirrhosis,
1 due to several reasons as follows: cirrhotic 
patients tend to be intravascular volume depletion state due 
to gastrointestinal bleeding, diuretics use, and lactulose-induced 
diarrhea. Furthermore, these patients are often exposed to 
nephrotoxic agents such as nonsteroidal anti-inflammatory 
drugs, contrast agents, and aminoglycoside. In addition, renal 
dysfunction usually progresses to hepatorenal syndrome 
(HRS) with progression of liver cirrhosis and portal hypertension.
2 
Patients with cirrhosis who develop HRS have very high 
mortality, and even with terlipressin and albumin only 40% 
respond and survive for 1 month after treatment.
3 Therefore, 
because renal dysfunction is directly linked to the mortality 
rate of cirrhotic patients, a precise assessment of renal 
function is required to estimate the prognosis and determine 
the correct therapeutic intervention and response.
Serum creatinine (Cr) is commonly used marker for the 
assessment of renal function in the general population. 
However, serum Cr level could be influenced by age, 
gender, ethnicity, protein intake, and muscle mass.
3 Serum 
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with liver cirrhosis. Impaired liver function, protein-calorie 
malnutrition and muscle wasting result in decreased Cr 
production.
4,5 Elevated serum bilirubin can interfere with the 
measurement of Cr by Jaffe method. In addition, ascites and 
peripheral edema can also decrease the Cr by widening the 
distribution of Cr in the body. Therefore, baseline serum Cr 
is low in cirrhotic patients compared to general population.
6,7 
It has been suggested that many patients with cirrhosis and 
ascites will have a low glomerular filtration rate (GFR) 
despite normal serum Cr level.
8 The Cockcroft and Gault and 
the modification of diet in renal disease (MDRD) equations 
are widely used in the general population to estimate GFR.
6,7 
However, because these equations are based on serum Cr 
levels, they are also inaccurate in cirrhotic patients.
Recently, it was reported that serum cystatin C (CysC) can 
be used alternative to serum Cr.
9 CysC is a low molecular 
weight protein produced at a constant rate by all nucleated 
cells and eliminated by glomerular filtration.
10 After filtration 
CysC is reabsorbed and catabolized by the tubular epithelial 
cells. In contrast to Cr, CysC is independent of gender, age, 
and muscle mass. The dosage is not influenced by serum 
bilirubin, inflammation, or malignancy.
3,11 In a recent meta- 
analysis, serum CysC was superior to serum Cr and had 
better correlation with GFR.
12 In a previous study, serum 
CysC was at least as accurate as serum Cr in patients with 
HRS.
13 Several reports have suggested that increased serum 
CysC levels are more sensitive for detecting renal dysfunction 
in patients with cirrhosis than increased serum Cr levels, and 
that measurement of serum CysC could offer good alternative 
to serum Cr for the assessment of renal function in these 
patients.
11,13-15
This study was performed to evaluate the frequency of 
renal dysfunction in patients with cirrhotic ascites and a 
normal serum Cr level and the clinical significance of CysC 
for the detection of the renal dysfunction in these patients.
PATIENTS AND METHODS
Patients
Consecutive patients with cirrhotic ascites and a normal 
serum Cr level (<1.2 mg/dL) who were admitted to the 
Korea University Anam Hospital between January 2008 and 
December 2009 were enrolled in this study. Patients with 
hepatocellular carcinoma, intrinsic renal disease, congestive 
heart failure, chronic obstructive pulmonary disease, spontaneous 
bacterial peritonitis, severe malnutrition, sepsis or gastroin-
testinal bleeding during the month before enrollment were 
excluded from the study. The diagnosis of cirrhosis was 
based on a combination of physical examination, laboratory 
tests, and imaging. Informed consent was obtained from 
each patient according to the Declaration of Helsinki, and 
the study protocol was approved by the local ethics committee 
at our hospital.
Laboratory analyses
Serum samples were obtained for the measurement of Cr, 
blood urea nitrogen (BUN) and CysC. Serum Cr levels were 
determined using the Dimension clinical chemistry system 
(Dade Behring, Marburg, Germany) with a commercially 
available assay based on the modified Jaffe method, as 
reported by Larsen.
16 The serum CysC assay was implemented 
using latex-particle-enhanced turbidimetric immunoassay 
PET (Dako, Glostrup, Denmark) on a CX7 analyzer (Beckman, 
CA, USA). The Dako Cystatin C PET kit contains polystyrene 
particles of uniform size that were chemically coupled to 
rabbit antibodies raised against human CysC. Biochemical 
tests, including for levels of aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), alkaline phosphatase, 
albumin and bilirubin, were implemented using routine 
laboratory methods. The Child-Pugh score was determined 
by applying Pugh’s commonly used modification, which is 
based on the presence and severity of ascites and hepatic 
encephalopathy, prolongation of the prothrombin time and 
levels of serum bilirubin and albumin.
17 The model for 
end-stage liver diseases (MELD) score was calculated 
according to the following equation: 9.57×loge (creatinine, 
mg/dL)+3.78×loge (bilirubin, mg/dL)+11.20×loge (INR)+6.43, 
where INR is the international normalized ratio and 6.43 is 
the constant for liver disease etiology.
18 The minimum value 
was set at 1.0 for calculation purposes. The maximum serum 
Cr level considered in the above equation was 4.0 mg/dL. 
GFR was measured by 
99mTc-DTPA renal scan. Images 
were obtained in supine position following an intravenous 
injection of 
99mTc-DTPA with a dose of 300 MBq. The data 
were acquired with a large field of view gamma camera 
equipped with a low energy, parallel hole general purpose 
collimator and an acquisition matrix. The first 60 s of the 
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Table 1. Baseline characteristics of enrolled patients with liver 
cirrhosis and ascites
Characteristics All patients (N=89)
Age (years) 55±11
Male, n  (%) 63 (70.8)
BMI (kg/m
2) 24.0±3.3
AST (IU/L) 107±94
ALT (IU/L) 63±81
Bilirubin (mg/dL) 5.3±6.8
Albumin (g/dL) 2.9±0.4
INR 1.6±0.6
Sodium (mEq/L) 136.1±4.5
BUN (mg/dL) 10.6±6.2
Creatinine (mg/dL) 0.8±0.2
Cystatin C (mg/L) 1.1±0.3
GFR (mL/min) 73.4±25.5
CCr (mL/min) 87.8±37.9
e-GFRC&G (mL/min) 54.3±21.3
e-GFRMDRD (mL/min) 113.5±34.8
Child-Pugh score 9.4±2.0
MELD score 21.0±11.8
Data are presented as mean±S.D.
BMI, body mass index; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; INR, international normalized 
ratio; BUN, blood urea nitrogen; GFR, glomerular filtration 
rate; CCr, Cr clearance; e-GFRC&G, glomerular filtration rate as
estimated using the formula of Cockcroft and Gault; e-GFRMDRD,
glomerular filtration rate as estimated using the modification 
of diet in renal disease equation; MELD, model for end-stage 
liver disease.
by a frame rate of 45 s/frame for a total duration of 20 
minutes. An image of glomerular filtration was generated on 
a pixel-by-pixel basis.
19 The basis of the filtration image is 
based on the kidney’s ability to take up the tracer from the 
blood, the image is independent of the volume of distribution 
of the tracer and any edema that may be present.
Significant renal impairment and severe renal impairment 
were defined as GFR <60 mL/min and GFR <30 mL/min, 
respectively, according to the National Kidney Foundation 
guidelines.
20 In addition, two kinds of estimated GFR 
(e-GFR) were calculated: (i) using the formula of Cockcroft 
and Gault (e-GFRC&G)
6 and (ii) using the MDRD equation 
(e-GFRMDRD).
7 Creatinine clearance (CCr) was calculated as 
a product of urinary Cr and 24-h urine volume divided by 
serum Cr (mg/dL) and multiplied by 1440.
Statistical analysis
Statistical analysis was performed using SPSS version 
13.0 (SPSS, Chicago, IL, USA). All data are expressed as 
either mean±standard deviation (SD) values or the number 
of patients (as a percentage of the entire cohort). Since 
distributions of continuous data were skewed, nonparametric 
methods were used for the group comparison and correlation 
analyses. Qualitative and quantitative differences between 
subgroups were analyzed using the χ² test and the Mann- 
Whitney U-test, respectively. Spearman’s correlation analysis 
was used to assess relationships between GFR and Cr, CysC, 
CCr, e-GFRC&G, e-GFRMDRD. Binary logistic regression analyses 
were performed for detection of patients with significant 
renal impairment. Odds ratios (ORs) and 95% confidence 
intervals (CIs) were calculated to determine the level of 
significance in the multivariate analysis. The predictive 
efficacy of a variable for predicting significant renal impairment 
was evaluated using a receiver operating characteristic 
(ROC) curve, with the area under the ROC curve (AUC) and 
95% CIs used as indices of accuracy. The optimal cutoff 
value for predicting significant renal impairment was 
determined based on the maximum total sensitivity and 
specificity. The cutoff for statistical significance was set at 
P<0.05.
RESULTS
Baseline characteristics
The baseline characteristics of the 89 enrolled patients 
with cirrhotic ascites are presented in Table 1. The age was 
55±11 years and 63 patients (70.8%) were male. Disease 
etiologies comprised alcohol (n=40, 44.9%), chronic hepatitis 
B (n=28, 31.5%), chronic hepatitis C (n=7, 7.9%), autoimmune 
liver disease (n=5, 5.6%), and cirrhosis of unknown etiology 
(n=9, 10.1%). Forty-seven (52.8%) and 42 (47.2%) patients 
were in Child-Pugh class B and C, respectively. Serum Cr 
and CysC levels and GFR were 0.8±0.2 mg/dL, 1.1±0.3 
mg/L, and 73.4±25.5 mL/min, respectively. Significant renal 
impairment and severe renal impairment were noted in 28 
(31.5%) and 2 (2.2%) patients, respectively.
Correlation of the variables with GFR
GFR was well correlated with 1/Cr (Spearman’s coefficient, 
0.242;  P=0.022) and 1/CysC (0.387; P<0.001), and Dong Jin Kim, et al. Cystatin C in patients with cirrhotic ascites  133
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Figure 1. Scatter plots of glomerular filtration rate (GFR) versus serum creatinine (A) and cystatin C (B) levels, creatinine clearance 
(C), e-GFRC&G  (D), and e-GFRMDRD  (E). 
CCr, creatinine clearance; e-GFRC&G, glomerular filtration rate as estimated using the formula of Cockcroft and Gault; e-GFRMDRD, 
glomerular filtration rate as estimated using the modification of diet in renal disease equation.
Table 2. Univariate and multivariate analysis of the variables for correlation with GFR
Variable Coefficient
* P
† P
‡ β (95% CI)
1/Cr 0.242 0.022 0.816
1/CysC 0.387 <0.001 <0.001 45.620 (23.042-68.198)
CCr 0.131 0.228
e-GFRMDRD 0.302 0.004 0.589
e-GFRC&G -0.086 0.422
* Spearman’s correlation coefficient; 
† univariate regression analysis; 
‡ multivariate regression analysis.
CI, confidence interval; Cr, creatinine; CysC, cystatin C; CCr, creatinine clearance; e-GFRC&G, glomerular filtration rate as estimated 
using the formula of Cockcroft and Gault; e-GFRMDRD, glomerular filtration rate as estimated using the modification of diet in renal 
disease equation.
e-GFRMDRD (0.302; P=0.004), while it was not correlated 
with e-GFRC&G (-0.086; P=0.422) (Fig. 1). In multiple linear 
regression analysis, only 1/CysC was significantly correlated 
with GFR (β, 45.620; 95% CI, 23.042-68.198; P<0.001) 
(Table 2).
Detection of significant renal impairment
Age, serum Cr and CysC levels, and e-GFRMDRD were 
significantly different between patients with significant 
renal impairment and the others (Table 3). However, serum 
CysC level was the only independent factor for predicting 
significant renal impairment (Table 4).
AUCs for predicting significant renal impairment of 
serum Cr and CysC levels, CCr, e-GFRC&G, and e-GFRMDRD 
were 0.615 (95% CI, 0.478-0.751), 0.721 (0.602-0.841), 
0.561 (0.430-0.691), 0.463 (0.331-0.594), and 0.659 (0.529- 
0.788), respectively (Fig. 2). Sensitivity, specificity, PPV, 
and NPV for predicting significant renal impairment 
according to the cutoff values of serum CysC level are 
presented in Table 5. Optimal cutoff value of serum CysC 134  The Korean Journal of Hepatology Vol. 17. No. 2, June 2011
Table 3. Baseline characteristics of enrolled patients with cirrhotic ascites according to their renal function
Characteristics Patients with GFR ≥60 mL/min (n=61) Patients with GFR <60 mL/min (n=28) P-value
*
Age (years) 53.1±10.3 58.8±12.9 0.046
Male, n  (%) 46 (75.4) 17 (60.7) 0.157
BMI (kg/m
2) 23.5±3.0 24.9±4.0 0.063
AST (IU/L) 107.0±88.7 106.5±106.2 0.982
ALT (IU/L) 61.4±81.1 67.6±81.1 0.741
Bilirubin (mg/dL) 4.6±4.9 6.9±9.8 0.259
Albumin (g/dL) 2.8±0.4 2.9±0.4 0.543
INR 1.6±0.7 1.6±0.6 0.933
Sodium (mEq/L) 135.7±4.6 137.1±3.5 0.169
BUN (mg/dL) 9.5±4.5 12.8±8.5 0.064
Creatinine (mg/dL) 0.7±0.2 0.8±0.2 0.045
Cystatin C (mg/L) 1.0±0.2 1.3±0.3 <0.001
CCr (mL/min) 90.0±37.6 82.8±38.9 0.412
e-GFRC&G (mL/min) 53.3±20.5 56.4±23.1 0.528
e-GFRMDRD (mL/min) 119.8±34.5 99.8±32.0 0.011
Child-Pugh score 9.4±2.0 9.6±2.0 0.591
MELD score 20.5±11.0 22.1±13.3 0.554
Data are presented as mean±S.D.
* Mann-Whitney  U test or chi-square test.
BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; BUN, 
blood urea nitrogen; GFR, glomerular filtration rate; CCr, Cr clearance; e-GFRC&G, glomerular filtration rate as estimated using the 
formula of Cockcroft and Gault; e-GFRMDRD, glomerular filtration rate as estimated using the modification of diet in renal disease 
equation; MELD, model for end-stage liver disease.
Table 4. Binary logistic regression analysis for detection of patients with significant renal impairment
Variable P β OR (95% CI)
Age 0.408
BMI 0.089
BUN 0.563
Creatinine 0.528
Cystatin C 0.002 2.926 18.653 (2.940-118.336)
e‐GFRMDRD 0.535
OR, odds ratio; CI, confidence interval; BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; e-GFRMDRD, glomerular 
filtration rate as estimated using the modification of diet in renal disease equation.
level was set at 1.1 mg/L. Serum CysC level was ≥1.1 mg/L 
in 37 patients (41.6%) and GFR was <60 mL/min in 19 of 
them (67.9%).
DISCUSSION
Many patients with liver cirrhosis and ascites will have a 
lower GFR but a normal serum Cr level.
8 In these patients, 
renal dysfunction usually progresses with liver cirrhosis and 
portal hypertension.
21 HRS is a functional renal failure that 
frequently develops in advanced cirrhotic patients. Splanchnic 
vasodilatation and reduced cardiac output plays a significant 
role for the development of HRS.
21 The incidence of HRS 
was 18% at 1 year and 39% at 5 years in advanced cirrhosis.
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Table 5. Sensitivity, specificity, PPV, and NPV for predicting significant renal impairment according to various cutoff values of 
serum cystatin C levels
Cutoff values of cystatin C Sensitivity (%) Specificity (%) PPV (%) NPV (%) Likelihood ratio
0.87 92.9 23.0 35.6 87.5 3.718
0.90 85.7 27.9 35.3 81.0 2.099
1.00 78.6 50.8 42.3 83.8 7.196
1.10 67.9 70.5 51.4 82.7 11.665
1.37 32.1 90.2 60.0 74.3 6.351
PPV, positive predictive value; NPV, negative predictive value.
Figure 2. Receiver operating characteristic curves of serum 
creatinine and cystatin C levels, CCr, e-GFRC&G, and e-GFRMDRD
for predicting significant renal impairment.
CCr, creatinine clearance; GFR, glomerular filtration rate; e-GFRC&G, 
glomerular filtration rate as estimated using the formula of 
Cockcroft and Gault; e-GFRMDRD, glomerular filtration rate as 
estimated using the modification of diet in renal disease equation.
In our previous study, the cumulative incidence of HRS at 1 
year of follow-up was 20.4%.
22 The prognosis of HRS 
is very poor. The median survival was only 1.7 weeks and 
the mortality rates at 1 and 2 months were 75% and 82%, 
respectively.
23 So, the development of renal dysfunction 
significantly affects the prognosis of the patients with 
cirrhosis. Several authors have suggested that renal function 
is better than liver function as a predictor of prognosis in 
these patients.
3,24,25 In our study, significant renal dysfunction 
was noted in 28 patients (31.5%) in patients with cirrhotic 
ascites, even their serum Cr levels were normal.
Serum Cr has been widely used as the standard laboratory 
marker for the assessment of renal function in general 
population. However, serum Cr could not represent GFR in 
several conditions, especially in liver disease.
8,26,27 Serum Cr 
is influenced by age, gender, ethnicity, muscle mass and 
protein intake.
28 Because Cr is a byproduct of the 
metabolism of the nitrogenous organic acid, creatine, which 
is stored in muscles, Cr reflects endogenous muscle mass as 
well as protein intake.
29 Routine Cr assay is based on 
spectrophotometry. In patients with jaundice, bilirubin 
interferes with Cr dosage as a chromogen, results in low Cr 
value.
30, 31 In addition, because creatine is synthesized in the 
liver, any cause of hepatic parenchymal dysfunction will 
directly reduce creatine production.
29 Decrease in the 
creatine production rate as well as malnutrition and muscle 
wasting in patients with liver cirrhosis lead to a markedly 
lower baseline Cr compared to the normal population.
32,33 
Therefore, serum Cr may overestimate renal function in 
these patients and normal serum Cr level cannot exclude 
early renal dysfunction in patients with liver cirrhosis.
8,26,34,35
CCr from timed urine collections might be a reliable 
method for renal function evaluation. However, several 
studies have shown that CCr overestimates true GFR about 
13 mL/min/1.73 m
3 compared to inulin clearance in patients 
with cirrhosis,
14,35-37 because the increased proportion of Cr 
secreted by the tubule compared to Cr filtered by the 
glomerulus in these patients.
36 Practically, nonspecific 
factors including incomplete urine collection due to hepatic 
encephalopathy and errors in the timing of collection may 
play a role in the inaccuracy of CCr. Consistently, CCr was 
not correlated with GFR (P=0.228) in this study.
The Cr-based e-GFRC&G and e-GFRMDRD are commonly 
used method to estimate GFR. However, as these equations 
are based on serum Cr, they are also inaccurate in patients 
with cirrhosis. Several studies have reported that both 
e-GFRC&G and e-GFRMDRD tend to overestimate true GFR.
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The inaccuracy of e-GFRC&G and e-GFRMDRD in cirrhotic 
patients may be related to several factors. At first, Cr is 
inaccurate marker of renal function in cirrhotic patients. 
Secondly, e-GFRC&G and e-GFRMDRD include serum Cr 
adjusted for several variables which were shown to have a 
significant impact on GFR in the general population (i.e., 
age, body weight and gender for e-GFRC&G; age, gender and 
ethnicity for e-GFRMDRD). These factors did not fit for 
cirrhotic patients. Finally, e-GFRC&G and e-GFRMDRD are not 
adjusted for some variables which are likely to have a 
determinant impact on the estimation of GFR in cirrhotic 
patients. e-GFRC&G relies on the serum Cr as well as the 
body weight which is difficult to define in patients with 
ascites. This formula has a sensitivity of only 50-60% for 
detecting a loss of GFR in patients with liver disease.
39 In 
cirrhotic patients, e-GFRMDRD is relatively more accurate 
than e-GFRC&G because it does not consider body weight.
40 
Consistently, GFR was significantly correlated with 
e-GFRMDRD, while not with e-GFRC&G in this study.
In this study, 1/Cr, 1/CysC, e-GFRMDRD, was well correlated 
with GFR in a univariate analysis, but only 1/CysC was 
significantly correlated with GFR in a multivariate analysis. 
The strength of this study is that we compared Cr, CysC, and 
CCr with directly measured GFR using 
99mTc-DTPA scan, 
rather than estimated GFR based on serum Cr level. 
However, it should be kept in mind that inulin clearance is 
still considered as gold standard for determination of GFR, 
although it is impractical because of the necessity for a 
continuous intravenous infusion and urine bladder catheter 
for urine collections over a period of several hours. In 
contrast, because radiolabeled tracers such as 
99mTc-DTPA, 
51Cr-EDTA, and 
125I-iothalamate require only a single 
injection and timed urine collection is not needed, these 
examinations could be more practical. Because 
99mTc-DTPA 
is filtered by the glomerulus, and neither reabsorbed nor 
excreted by the tubules, 
99mTc-DTPA renal scan offers the 
possibility to estimate both renal perfusion and glomerular 
filtration.
41 A 20 minutes 
99mTc-DTPA renal scan with a 
gamma camera allows semi-quantitative analysis of the 
perfusion and filtration phases but absolute quantification is 
fraught with difficulty on the gamma camera.
41 In addition, 
GFR obtained by these examinations may overestimate 
compared to GFR obtained by inulin clearance.
42,43 Usually, 
all plasma-clearance techniques become somewhat inaccurate 
in conditions with GFR values below 20-30 mL/min.
44
We had expected that serum CysC level could be a good 
marker of renal dysfunction in patients with normal serum 
Cr level in cirrhotic patient with ascites. In accordance with 
our expectation, serum CysC was a good marker of early 
renal dysfunction in patient with cirrhotic ascites and normal 
Cr levels. The cutoff value of 1.1 mg/dL could be an 
adequate reference level for detecting early renal dysfunction 
in these patients. In this study, there was no significant 
difference in MELD and Child Pugh score between normal 
and impaired renal function group, probably because we 
enrolled advanced cirrhosis patients who already have 
decompensated cirrhosis with ascites. Our results were 
consistent with previous studies.
13,15,45-47 However, evaluation 
of renal function using serum CysC levels has several 
limitations. Firstly, CysC assay is more expensive than serum 
Cr assay. Secondly, the assays need more standardization.
48 
Lastly, serum CysC is influenced by infection and some 
drugs such as corticosteroids, angiotensin-converting enzyme 
inhibitors or calcineurin inhibitors (CNI).
49,50
In conclusion, significant renal dysfunction is not rare in 
patients with cirrhotic ascites, even their Cr level is normal. 
Serum CysC could be a useful marker for detecting 
significant renal dysfunction in these patients.
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